Personalized immune cells battle tough lymphoma in major trial

NCT ID NCT03570892

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This large, completed Phase 3 trial tested whether a personalized cell therapy called tisagenlecleucel (a type of CAR-T) works better than standard chemotherapy and stem cell transplant for adults with aggressive B-cell non-Hodgkin lymphoma that returned or didn't respond to initial treatment. The study directly compared how long patients lived without their cancer getting worse and their overall survival between the two treatment approaches. It involved 331 participants who were randomly assigned to receive either the new cell therapy or the standard treatment plan.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Amsterdam UMC, locatie AMC

Amsterdam, 1105 AZ, Netherlands
Emory University

Atlanta, Georgia, 30329, United States
Hackensack Uni Medical Center

Hackensack, New Jersey, 07601, United States
Hokkaido University Hospital

Sapporo, Hokkaido, 060 8648, Japan
Jewish Hospital

Cincinnati, Ohio, 45236, United States
Kyushu University Hospital

Fukuoka, Fukuoka, 812-8582, Japan
MUSC Hollings Cancer Center

Charleston, South Carolina, 29425, United States
Mayo Clinic Jacksonville

Jacksonville, Florida, 32224, United States
Methodist Hospital

San Antonio, Texas, 78229, United States
Moores UC San Diego Cancer Center

La Jolla, California, 92093, United States
Novartis Investigative Site

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site

Murdoch, Western Australia, 6150, Australia
Novartis Investigative Site

Salzburg, 5020, Austria
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Salvador, Estado de Bahia, 41253-190, Brazil
Novartis Investigative Site

São Paulo, 05651-901, Brazil
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Beijing, 100191, China
Novartis Investigative Site

Shanghai, 200065, China
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Montpellier, 34295, France
Novartis Investigative Site

Nantes, 44093, France
Novartis Investigative Site

Paris, 75475, France
Novartis Investigative Site

Pierre-Bénite, 69495, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Munich, Bavaria, 81377, Germany
Novartis Investigative Site

Regensburg, Bavaria, 93053, Germany
Novartis Investigative Site

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Hamburg, 20246, Germany
Novartis Investigative Site

Ulm, 89081, Germany
Novartis Investigative Site

Hong Kong, Hong Kong
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Roma, RM, 00168, Italy
Novartis Investigative Site

Sapporo, Hokkaido, 0608648, Japan
Novartis Investigative Site

Sendai, Miyagi, 9808574, Japan
Novartis Investigative Site

Fukuoka, 8128582, Japan
Novartis Investigative Site

Amsterdam, North Holland, 1081 HV, Netherlands
Novartis Investigative Site

Utrecht, 3584 CX, Netherlands
Novartis Investigative Site

Oslo, 0310, Norway
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 169608, Singapore
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Salamanca, 37007, Spain
Novartis Investigative Site

Zurich, 8091, Switzerland
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Birmingham, West Midlands, B15 2TH, United Kingdom
Novartis Investigative Site

London, NW1 2BU, United Kingdom
Oregon Health Sciences Univ

Portland, Oregon, 97239, United States
Sarah Cannon Research Institute

Denver, Colorado, 80218, United States
St Davids South Austin Medical Ctr

Austin, Texas, 78704, United States
Tennessee Oncology PLLC

Chattanooga, Tennessee, 37404, United States
Texas Oncology-Baylor Scott and White

Dallas, Texas, 75231, United States
The Ohio State University

Columbus, Ohio, 43210, United States
Tohoku University Hospital

Sendai, Miyagi, 980 8574, Japan
UCSF Medical Center

San Francisco, California, 94143, United States
UMC Utrecht Cancer Center

Utrecht, 3584CX, Netherlands
Uni Pennsylvania Abramson Cncr Ctr

Philadelphia, Pennsylvania, 19104, United States
Uni of Chi Medi Ctr Hema and Onco

Chicago, Illinois, 60637, United States
Uni of Nebraska Med Ctr

Omaha, Nebraska, 68198, United States
Uni of Texas MD Anderson Ca Center

Houston, Texas, 77030, United States
Uni of Wisconsin Carbone Cancer Ctr

Madison, Wisconsin, 53792-6164, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66205, United States
Wayne State University-Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

Conditions

Explore the condition pages connected to this study.

NON-HODGKIN LYMPHOMA